Therapeutic Approach for Metastatic Renal Cell Carcinoma
Therapeutic Approach for Metastatic Renal Cell Carcinoma
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
- A 73-year old woman with clear cell RCC, hyperlipidemia, and type 2 diabetes, which are both managed medically
- Her baseline patient and disease characteristics were:
- ECOG PS 0, KPS 90
- pT3bNxM0 (AJCC stage 3)
- 5-cm left kidney tumor mass with extension into the left renal vein
- She underwent radical nephrectomy within 1 month following diagnosis
December 2017
- The patient reported loss of appetite and weight loss
- CT imaging showed multiple liver lesions, 2 small nodules in the right lung upper lobe, and mediastinal lymphadenopathy
- Laboratory findings notable for Ca2+ 14.8 mg/dL
- PD-L1 expression, <1%
- Remarks: RCC disease progression; IMDC risk stratification, intermediate
- The patient was started on cabozantinib, 60 mg daily
- After 4 weeks on therapy she developed grade 2 diarrhea and her dose was reduced to 40 mg
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
